FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3082452399> ?p ?o ?g. }

• W3082452399 endingPage "3389" @default.
• W3082452399 startingPage "3389" @default.
• W3082452399 abstract "Abstract Introduction: Hematopoietic Cell Transplantation (HCT) activity in the EMRO/African (EMRO/AFR) region was compared to the global activity in relation to frequency, indication, trends, donor type and geographical distribution. Methods: Surveys were obtained from international and national registries or by direct reporting by individual centers from 2006-2013. In 2013, activities were summarized from a total of 1570 teams in 78 countries over 6 WHO continental regions. Of these 1570 teams, only 29 teams were active in 12 countries of the EMRO/AFR region. Results: A total of 464,100 HCT have been reported worldwide since 2006, 54% of which were autologous and 46% allogeneic. The most frequent indications were lymphoproliferative disorders (53.1%), leukemias (35.5%), non-malignant diseases (6.2%), solid tumors (4.9%) and other non-specified rare diseases (0.3%). The annual HSCT activity increased by 52.6% from 46,543 in 2006 to 71,036 in 2013, primarily among allogeneic HSCT (+65%), particularly for non-malignant disorders (+86%), acute leukemias/MDS/MPN (+80%) and lymphoproliferative disorders (+42%). Of the allogeneic HSCT, 106,662 (49.8%) were performed from a family donor. Frequencies of autologous HSCT rose from 26,230 to 37,464 between 2006 and 2013 (+42.8%) primarily for Plasma Cell Disorders (PCD; +75.8%), non-malignant diseases (+50.3%) and lymphomas (+33.7%). Only 2.331 of the 71.036 HCT in 2013 were performed in the EMRO/AFR region. This represents a 90% increase from 2006, characterized by a high frequency of allogeneic compared to autologous HCT and by the almost exclusive use of family donors. Alternative HSCT in the EMRO/AFR region tended to use haploidentical donors rather than cord blood. This contrasts with the global activities, where the frequency of haploidentical HCT did not start to increase until 2012. There was an increase of 200% in HCT for hemoglobinopathies (Thalassemia and Sickle cell anemia; from 72/year in 2006 to 216/year in 2013), but this remains lower than in all other world regions. A total of 1033 HCT for hemoglobinopathies were performed globally in 2013 representing an increase of 164% from 2006 (n=392). This is an extremely low number considering the high prevalence and incidence of Thalassemia (40.000 born annually and 80 million carriers; Modell, WHO Bulletin 2008) and of sickle cell anemia patients in the EMRO/AFR region (e.g. 91,011 in Nigeria and 39,743 in Congo). Conclusion: The global data on HCT demonstrate the benefits of intensive global collaboration and data sharing, but illustrate important unmet needs, especially the continued underuse of HCT in the region despite evident progress. This information establishes a basis for competent authorities to provide adequate infrastructure and to improve the current situation in which access often remains limited. Disclosures Greinix: Sanofi: Consultancy, Speakers Bureau; Bristol Myers Squibb: Consultancy, Speakers Bureau; Mallinckrodt: Consultancy, Speakers Bureau; Novartis: Consultancy, Speakers Bureau; Amgen: Consultancy, Speakers Bureau; Celgene: Consultancy, Speakers Bureau. Szer: Alexion Pharmaceuticals, Inc.: Consultancy, Honoraria, Other: Travel Support, Research Funding." @default.
• W3082452399 created "2020-09-08" @default.
• W3082452399 creator A5006011073 @default.
• W3082452399 creator A5013822331 @default.
• W3082452399 creator A5015511458 @default.
• W3082452399 creator A5016164636 @default.
• W3082452399 creator A5018234201 @default.
• W3082452399 creator A5018523027 @default.
• W3082452399 creator A5020002610 @default.
• W3082452399 creator A5020602973 @default.
• W3082452399 creator A5023108730 @default.
• W3082452399 creator A5024318187 @default.
• W3082452399 creator A5025836945 @default.
• W3082452399 creator A5041363302 @default.
• W3082452399 creator A5042734609 @default.
• W3082452399 creator A5043033429 @default.
• W3082452399 creator A5043706544 @default.
• W3082452399 creator A5044710516 @default.
• W3082452399 creator A5048148064 @default.
• W3082452399 creator A5055032061 @default.
• W3082452399 creator A5055094076 @default.
• W3082452399 creator A5058332719 @default.
• W3082452399 creator A5060292533 @default.
• W3082452399 creator A5066468781 @default.
• W3082452399 creator A5070132319 @default.
• W3082452399 creator A5070673184 @default.
• W3082452399 creator A5070706427 @default.
• W3082452399 creator A5072151390 @default.
• W3082452399 creator A5072582820 @default.
• W3082452399 creator A5073625002 @default.
• W3082452399 creator A5075853787 @default.
• W3082452399 creator A5081654849 @default.
• W3082452399 creator A5083504452 @default.
• W3082452399 creator A5086834338 @default.
• W3082452399 creator A5086980259 @default.
• W3082452399 creator A5088510178 @default.
• W3082452399 creator A5090186929 @default.
• W3082452399 creator A5091433944 @default.
• W3082452399 date "2017-12-07" @default.
• W3082452399 modified "2023-09-27" @default.
• W3082452399 title "Narrowing the Gap for Hematopoietic Cell Transplantation in the East-Mediterranean/African Region: Comparison with Global HSCT Indications and Trends. A Report on Behalf of the East Mediterranean (EMBMT), African Blood and Marrow Transplantation Group (AFBMT) and Worldwide Network for Blood and Marrow Transplantation (WBMT)" @default.
• W3082452399 doi "https://doi.org/10.1182/blood.v130.suppl_1.3389.3389" @default.
• W3082452399 hasPublicationYear "2017" @default.
• W3082452399 type Work @default.
• W3082452399 sameAs 3082452399 @default.
• W3082452399 citedByCount "0" @default.
• W3082452399 crossrefType "journal-article" @default.
• W3082452399 hasAuthorship W3082452399A5006011073 @default.
• W3082452399 hasAuthorship W3082452399A5013822331 @default.
• W3082452399 hasAuthorship W3082452399A5015511458 @default.
• W3082452399 hasAuthorship W3082452399A5016164636 @default.
• W3082452399 hasAuthorship W3082452399A5018234201 @default.
• W3082452399 hasAuthorship W3082452399A5018523027 @default.
• W3082452399 hasAuthorship W3082452399A5020002610 @default.
• W3082452399 hasAuthorship W3082452399A5020602973 @default.
• W3082452399 hasAuthorship W3082452399A5023108730 @default.
• W3082452399 hasAuthorship W3082452399A5024318187 @default.
• W3082452399 hasAuthorship W3082452399A5025836945 @default.
• W3082452399 hasAuthorship W3082452399A5041363302 @default.
• W3082452399 hasAuthorship W3082452399A5042734609 @default.
• W3082452399 hasAuthorship W3082452399A5043033429 @default.
• W3082452399 hasAuthorship W3082452399A5043706544 @default.
• W3082452399 hasAuthorship W3082452399A5044710516 @default.
• W3082452399 hasAuthorship W3082452399A5048148064 @default.
• W3082452399 hasAuthorship W3082452399A5055032061 @default.
• W3082452399 hasAuthorship W3082452399A5055094076 @default.
• W3082452399 hasAuthorship W3082452399A5058332719 @default.
• W3082452399 hasAuthorship W3082452399A5060292533 @default.
• W3082452399 hasAuthorship W3082452399A5066468781 @default.
• W3082452399 hasAuthorship W3082452399A5070132319 @default.
• W3082452399 hasAuthorship W3082452399A5070673184 @default.
• W3082452399 hasAuthorship W3082452399A5070706427 @default.
• W3082452399 hasAuthorship W3082452399A5072151390 @default.
• W3082452399 hasAuthorship W3082452399A5072582820 @default.
• W3082452399 hasAuthorship W3082452399A5073625002 @default.
• W3082452399 hasAuthorship W3082452399A5075853787 @default.
• W3082452399 hasAuthorship W3082452399A5081654849 @default.
• W3082452399 hasAuthorship W3082452399A5083504452 @default.
• W3082452399 hasAuthorship W3082452399A5086834338 @default.
• W3082452399 hasAuthorship W3082452399A5086980259 @default.
• W3082452399 hasAuthorship W3082452399A5088510178 @default.
• W3082452399 hasAuthorship W3082452399A5090186929 @default.
• W3082452399 hasAuthorship W3082452399A5091433944 @default.
• W3082452399 hasConcept C109159458 @default.
• W3082452399 hasConcept C126322002 @default.
• W3082452399 hasConcept C187212893 @default.
• W3082452399 hasConcept C203014093 @default.
• W3082452399 hasConcept C2776995267 @default.
• W3082452399 hasConcept C2777408962 @default.
• W3082452399 hasConcept C2779338263 @default.
• W3082452399 hasConcept C28328180 @default.
• W3082452399 hasConcept C2911091166 @default.
• W3082452399 hasConcept C2993713153 @default.
• W3082452399 hasConcept C54355233 @default.
• W3082452399 hasConcept C71924100 @default.
• W3082452399 hasConcept C86803240 @default.
• W3082452399 hasConceptScore W3082452399C109159458 @default.
• W3082452399 hasConceptScore W3082452399C126322002 @default.

• next